A single 25-milligram dose of psilocybin significantly reduced anhedonia, the loss of ability to feel pleasure, in patients with treatment-resistant depression, according to a clinical trial reported on November 17, 2026, by researchers at the University of Colorado Anschutz Medical Campus.
The improvement was measured eight weeks after treatment. Anhedonia is considered one of the most difficult symptoms of depression to address, because standard antidepressants that act on serotonin often ease low mood without fully restoring motivation or enjoyment. Patients who experience it tend to have poorer outcomes and higher rates of relapse.
Psilocybin is the psychoactive compound found in certain mushrooms. In clinical research it is typically given in a controlled setting with psychological support before, during and after the session. A large trial published in the New England Journal of Medicine in 2022 found that a 25-milligram dose reduced depressive symptoms in people with treatment-resistant depression over three weeks.
Psilocybin remains a Schedule I substance under U.S. federal law, though the Food and Drug Administration has granted breakthrough therapy designation to psilocybin treatments for depression. Colorado voters approved regulated access to natural psychedelics in 2022.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.eurekalert.org/news-releases/1152292